Hypertension Diagnosis Companies, Investment and Capital Allocation

Top Companies in the Hypertension Diagnosis Market with Latest Offerings

Market Growth

The hypertension diagnosis market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2026 to 2035. This growth is driven by emerging trends and strong demand across key sectors.

Companies and their Offerings

Beurer GmbH

Headquarter: Germany
Offerings: Offers a wide range of health and well-being products, including blood pressure monitors, blood glucose meters, ECG devices, pulse oximeters, thermometers, and connected health solutions.

Kaz Inc. / Kaz USA Inc.

Headquarter: Massachusetts, USA
Offerings: Produces and distributes healthcare and home comfort products such as blood pressure monitors, thermometers, humidifiers, air purifiers, and hot/cold therapy devices under brands like Vicks and Braun.

Panasonic Healthcare (PHC Holdings)

Headquarter: Tokyo, Japan
Offerings: Focuses on healthcare technologies, including laboratory freezers, sterilization equipment, and related medical devices; it is the healthcare arm stemming from the Panasonic brand.

NISSEI (Nihon Seimitsu Sokki Co., Ltd.)

Headquarter: Gunma, Japan
Offerings: Specializes in precision medical instruments, especially digital blood pressure monitors (upper-arm and wrist types), pulse oximeters, thermometers, and related diagnostic equipment for professional and home use.

Yuwell

Headquarter: Jiangsu, China
Offerings: A leading medical device manufacturer offering blood pressure monitors, oxygen concentrators, thermometers, nebulizers, and other healthcare products for clinical and home settings.

Contec Medical Systems Co., Ltd.

Headquarter: Qinhuangdao, China
Offerings: Provides a broad range of medical devices, including blood pressure monitors, ambulatory and electronic sphygmomanometers, ECG systems, patient monitors, and diagnostic instrumentation.

What are the Recent Developments in the Hypertension Diagnosis Market?

In July 2025, Sanofi acquired Blueprint Medicines to expand its oncology and rare disease portfolio, supporting its broader strategy of diversification and long term therapeutic growth.

In February 2025, Novartis acquired Anthos Therapeutics in a deal valued at up to USD 3.1 billion. The acquisition strengthens Novartis’ cardiovascular portfolio, with a focus on advancing innovative therapies for hypertension and heart disease.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com